Eleusis' drug will slot into Beckley's pipeline alongside lead drug BPL-003, an intranasal formulation of psychoactive compound 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) heading for phase 2 ...

DMT S.A. (BP 270, Savoie-Technolac, F-73375 Le Bourget du Lac), which was only founded in 1990 by its current owners, Darlet and Marchante, has emerged as one of the world's leading suppliers of ...

The money is also earmarked for a phase 1 dose-ranging study on an intranasal formulation of 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), a psychedelic compound found in plants and at least one ...

Anecdotal evidence suggests that low, nonhallucinogenic doses of psychedelics can reduce symptoms of schizophrenia and psychosis. 5-Methoxy-N,N-dimethyltryptamine (5-MeO–DMT) has demonstrated ...